Introduction {#sec1}
============

Sudden sensorineural hearing loss (SSHL) or sudden deafness, is typically defined as a hearing loss of at least 30 decibels occurring over at least three consecutive frequencies and lasting at least 3 days \[[@B1]\]. The estimated incidence varies from approximately 5 to 20 up to 160 per 100000 people per year \[[@B2]\]. The patient typically first notices symptoms upon awakening and describes an aural fullness/blockage. They may also experience tinnitus (usual), dizziness, or vertigo \[[@B1]\]. SSHL is considered to be a medical emergency, and, as such, requires prompt evaluation and treatment \[[@B3]\]. So far, the diagnosis and monitor of SSHL are mainly dependent on audio acuity, eardrum test and imaging, lacking of simple and quick serum markers. Recent years, many studies have showed that vascular events (vascular occlusions, hypostasis, ischemia, etc.) are assumed to be involved with the pathogenesis of SSHL \[[@B4]\]; therefore, some researchers focus on the clinical significance of platelet parameters (mean platelet volume (MPV), platelet distribution width (PDW), and platelet count (PLT)) in SSHL to explore whether platelet parameters can sever as markers to provide assistant for diagnosis and monitor of SSHL. However, it is a controversial topic whether platelet parameters are associated with SSHL, some hold positive attitude \[[@B7]\] and some are in the opposite \[[@B10]\]. Therefore, we carry out this systematic review and meta-analysis to expect to solve this controversy and provide clinical evidence for diagnosis and monitor of SSHL.

Materials and methods {#sec2}
=====================

Literature search and selection criteria {#sec2-1}
----------------------------------------

This systematic review and meta-analysis is reported in accordance with the Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) Statement. Studies were retrieved by searching electronic databases (PubMed, Embase, Cochrane and Scopus) and searching references of related articles by hand. These computer searches were from the creation of the databases up to December 2017. Retrieval strategy of PubMed as follows: (((((Sudden Hearing Loss or Deafness, Sudden or Sudden Deafness))) OR "Hearing Loss, Sudden" \[Mesh\])) AND (((((platelet count) OR platelet)) OR ((platelet distribution width) OR PDW)) OR (("Mean Platelet Volume" \[Mesh\]) OR mean platelet volume)).

The inclusion criteria were as follows: (1) Participants: SSHL patients without other illness related to platelet activity, such as venous thrombosis, cardiovascular disease; (2) Exposures: platelet parameters level; (3) Comparatives: healthy controls; (4) Type of studies: independent case--controlled studies using either a hospital-based or population-based design; (5) Publications with English or Chinese, the latter must be on Medline.

Exclusion criteria included the following: (1) Duplicated data; (2) Case reports and studies where the original data could not be extracted; (3) Animal experiments and basic research; (4) Reviews and letters.

Data extraction {#sec2-2}
---------------

Two authors (S.F. Ji and X.M. Chen) independently extracted the original data. Disagreement was resolved by discussion. If the two authors could not reach a consensus, the result was reviewed by a third author (H. Shi). The extracted data consisted of the following items: the first author's name, publication year, population (ethnicity), methods, study design, matching criteria, sex, total number of cases and controls, and age (years).

Quality assessment {#sec2-3}
------------------

The Newcastle-Ottawa Scale (NOS) was used to assess the methodological quality of the individual studies. Each study was evaluated and scored based on three criteria: selection (4 stars), comparability (2 stars), and exposure (3 stars). The NOS point scale ranged from 0 to 9 stars, the researches with NOS ≥7 stars were considered high quality.

Statistical analysis {#sec2-4}
--------------------

We utilized Review manager 5.3 and Stata 14.0 software to perform the meta-analysis in the present study. Heterogeneity among studies was assessed by the *I*^2^ statistic, and *P*\<0.10 and *I*^2^ \> 50% indicated evidence of heterogeneity. If heterogeneity existed among the studies, a random-effects model was used to estimate the pooled standard mean difference (SMD). Otherwise, a fixed-effects model was adopted. The SMD and corresponding 95% confidence interval (CI) were utilized to assess the associations. Subgroups analysis regarding geographical area, median of detection of patients, sample size, with EDTA anticoagulation treatment and NOS quality, were also performed to explore source of heterogeneity. Egger's and Begg's tests (*P*\<0.05) can demonstrate a statistically significant publication bias and were conducted with the Stata 14.0 software, if there was any publication bias, trim, and fill method was implemented. Sensitive analysis was also conducted by changing effect model.

Results {#sec3}
=======

Selection and characteristics of studies {#sec3-1}
----------------------------------------

We retrieved a total of 152 studies in the literature search ([Figure 1](#F1){ref-type="fig"}). After duplicates were removed, only 88 full-text studies remained. Then, 70 articles, with 45 no-related reports, 17 reviews and letters, 2 animals research, 4 case reports and 2 insufficient-data studies, were excluded after screening abstracts and full-texts. Finally, 18 case--control studies were included \[[@B7]\], 12 studies mentioned MPV \[[@B7],[@B16],[@B24]\], 5 studies detected PDW \[[@B7],[@B8],[@B12],[@B16],[@B17]\], and 16 studies reported PLT level \[[@B7],[@B12],[@B13],[@B15]\]. And 11 studies were performed in Turkey \[[@B7],[@B8],[@B10],[@B15],[@B17],[@B23]\], 3 in China \[[@B20],[@B21],[@B24]\], 2 in Korea \[[@B9],[@B23]\], 1 in the Czech Republic \[[@B14]\], and 1 in Iran \[[@B16]\]. Details about NOS assessment and PRISMA are in Supplementary S1 and Supplementary S2. The characteristics of the eligible studies are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.

![Flow diagram for literature selection](bsr-38-bsr20181183-g1){#F1}

###### Main characteristics of eligible studies

  First author (location, year)             Group     Subjects (*N*)   Age (years)                                Male/Female   NOS
  ----------------------------------------- --------- ---------------- ------------------------------------------ ------------- -----
  Durmus (Turkey, 2016) \[[@B8]\]           Case      140              47.65 ± 16.14                              88/52         7
                                            Control   132              44.42 ± 16.22                              32/100        
  Mirvakili (Iran, 2016) \[[@B16]\]         Case      108              45.15 ± 14.42                              61/47         8
                                            Control   108              43.15 ± 11.54                              61/47         
  Ozturk (Turkey, 2014) \[[@B12]\]          Case      39               39.1 ± 12.8                                23/16         6
                                            Control   40               38.9 ± 11.2                                19/21         
  Ulu (Turkey, 2013) \[[@B7]\]              Case      40               44.6 ± 16.4                                20/20         8
                                            Control   40               46.8 ± 9.5                                 23/17         
  Sagit (Turkey, 2012) \[[@B17]\]           Case      31               37.45 ± 15.70                              17/14         8
                                            Control   31               35.77 ± 14.93                              16/15         
  Lee (Korea, 2017) \[[@B9]\]               Case      46               14.70 ± 2.81                               26/20         8
                                            Control   46               15.20 ± 2.28                               30/16         
  Kum (Turkey, 2015) \[[@B13]\]             Case      59               46.10 ± 11.91                              38/21         8
                                            Control   59               42.84 ± 11.85                              31/28         
  Sun (China, 2017) \[[@B24]\]              Case      129              43.77 ± 14.44                              68/61         8
                                            Control   31               51.06 ± 10.01                              16/15         
  Ezerarslan (Turkey, 2016) \[[@B18]\]      Case      62               51 ± 19                                    26/36         7
                                            Control   49               49 ± 16.2                                  16/33         
  Karli (Turkey, 2013) \[[@B10]\]           Case      46               45.39 ± 15.70                              25/21         8
                                            Control   46               41.38 ± 16.70                              24/22         
  Koçak (Turkey, 2016) \[[@B11]\]           Case      93               32.3 ± 7.9                                 41/52         8
                                            Control   93               31.4 ± 8.1                                 46/47         
  Bláha (Czech Republic, 2014) \[[@B14]\]   Case      54               54.2 ± 14.9                                32/22         6
                                            Control   38               32.6 ± 7.4                                 19/19         
  Bulğurcu (Turkey, 2017) \[[@B23]\]        Case      21               13.7 ± 3.2                                 13/8          6
                                            Control   24               14.8 ± 2.9                                 12/12         
  İkincioğullar (Turkey, 2014) \[[@B19]\]   Case      102              48.94 ± 13.86                              54/48         8
                                            Control   119              47 ± 9.63                                  65/54         
  Koçak (Turkey, 2017) \[[@B15]\]           Case      45               31.1 ± 7.4                                 25/20         8
                                            Control   47               32.4 ± 8.1                                 19/28         
  Seo (Korea, 2014) \[[@B22]\]              Case      348              48.19 ± 15.22                              171/177       7
                                            Control   537              48.22 ± 11.6                               288/249       
  Bao (China, 2015) \[[@B21]\]              Case      424              44.22 ± 14.92                              216/208       5
                                            Control   244              42.35 ± 14.71                              132/112       
  Lu (China, 2008) \[[@B20]\]               Case      50               14--69[\*](#T1TFN1){ref-type="table-fn"}   32/18         5
                                            Control   50               14--69[\*](#T1TFN1){ref-type="table-fn"}   32/18         

Range.

###### Main characteristics of eligible studies

  Study           MPV (fl)       PDW (fl)      PLT (10^3^/μl)                                                                         
  --------------- -------------- ------------- ---------------- -------------- -------------- ---- ---------------- ----------------- ----
  Durrmus         8.98 ± 1.73    9.12 ± 0.84   &                17.39 ± 6.27   10.06 ± 1.99   \#   228.33 ± 65.21   258.59 ± 50.63    \#
  Mirvakili       10.02 ± 0.76   9.85 ± 0.67   &                12.45 ± 1.50   12.11 ± 1.24   &    228.51 ± 62.45   222.86 ± 36.80    &
  Ozturk          8.19 ± 1.07    8.01 ± 1.05   &                17.7 ± 0.89    17.6 ± 1.04    &    257 ± 57         268 ± 63          &
  Ulu             10.5 ± 0.9     9.6 ± 0.5     \#               13.4 ± 2.1     11.1 ± 1.0     \#   232.9 ± 59.8     276.5 ± 62.1      \#
  Sagit           9.01 ± 1.24    8.21 ± 0.76   \#               16.29 ± 1.10   14.65 ± 2.13   \#   258.03 ± 58.28   249.06 ± 61.96    &
  Lee             7.89 ± 0.92    8.27 ± 0.74   \#                                                  287.52 ± 59.36   286.22 ± 55.99    &
  Kum             9.83 ± 1.50    9.98 ± 0.07   &                                                   249.44 ± 48.16   244.86 ± 47.25    &
  Sun             10.47 ± 1.43   9.75 ± 1.66   \#                                                  217.46 ± 53.67   202.48 ± 46. 61   &
  Ezerarslan      8.1 ± 1.2      8.4 ± 1.2     &                                                   234 ± 53.5       236 ± 39          &
  Karli           8.25 ± 0.86    7.98 ± 0.87   &                                                   243 ± 81.5       275 ± 82.5        &
  Koçak^1^        8.2 ± 2.2      8.7 ± 1.3     &                                                                                      
  Bláha           10.68 ± 1.1    10.47 ± 0.8   &                                                                                      
  Bulğurcu                                                                                         247.12 ± 53.23   262.11 ± 41.18    &
  İkincioğullar                                                                                    263.27 ± 64.11   259.32 ± 64.80    &
  Koçak^2^                                                                                         257 ± 61         257 ± 47          &
  Seo                                                                                              252.40 ± 60.07   238.64 ± 49.98    \#
  Bao                                                                                              240.47 ± 41.75   229.51 ± 48.88    \#
  Lu                                                                                               210.72 ± 49.40   205.52 ± 47.78    &

Koçak^1^, (Turkey, 2016); Koçak^2^, (Turkey, 2017). ^\#^*P*\<0.05, ^&^*P*≥0.05.

Meta-analysis {#sec4}
=============

Differences of MPV between SSHL patients and controls {#sec4-1}
-----------------------------------------------------

There were 12 studies reporting the association between MPV level and SSHL compared with control groups ([Figure 2](#F2){ref-type="fig"}). An *I*^2^ test indicated that the heterogeneity was significant (*I*^2^ = 80%, *P*\<0.00001), therefore, a random-effects model was applied to perform the meta-analysis. The results showed that MPV level in the SSHL group was not different from that in the control group \[SMD (95% CI) = 0.16 (−0.07, 0.40)\]. The weights were evenly distributed, and sensitive analysis showed that re-synthesized result was similar to previous one after fixed-effects model conducted \[SMD (95% CI) = 0.09 (−0.02, 0.19)\], which suggested the result is reliable. In addition, Egger's test (*P*=0.097) and Begg's test (*P*=0.193) showed that there was no publication bias ([Figure 3](#F3){ref-type="fig"}). Subgroup analysis ([Table 3](#T3){ref-type="table"}) by geographical area demonstrated that there were no significant difference both in Eastern countries \[SMD (95% CI) = 0.05(−0.93,1.02)\] and Western countries \[SMD (95% CI) = 0.18 (−0.07,0.43)\], and the similar results appeared in sample size ≥100 \[SMD (95% CI) = 0.20 (−0.15, 0.54)\] and \<100 \[SMD (95% CI) = 0.15 (−0.17,0.48)\], NOS ≥7 \[SMD (95% CI) = 0.16 (−0.12, 0.44)\] and \<7 \[SMD (95% CI) = 0.19 (−0.11,0.49)\], and EDTA with mentioned \[SMD (95% CI) = 0.42 (−0.00, 0.85)\] and no-mentioned \[SMD (95% CI) = −0.02 (−0.28, 0.24)\]. Result of sensitive analysis showed there did not appear significant change \[SMD (95% CI) = 0.09 (−0.02, 0.19)\].

![Difference of MPV between SSHL patients and controls](bsr-38-bsr20181183-g2){#F2}

![Begg's test (**A**) and Egger's test (**B**) for publication bias assessment of MPV.](bsr-38-bsr20181183-g3){#F3}

###### Summary effects of subgroup analysis results

  Subgroup                  *N*^\#^     SMD (95% CI)            *P*-value   Heterogeneity   
  ------------------------- ----------- ----------------------- ----------- --------------- ----
  **MPV**                   837/713     0.16 (--0.07, 0.40)     =0.18       \<0.00001       80
  Geographical area                                                                         
    Eastern country         165/77      0.05 (--0.93,1.02)      =0.93       =0.0007         91
    Western country         672/636     0.18 (--0.07, 0.43)     =0.15       \<0.00001       80
  Sample size of patients                                                                   
    Size ≥100               367/271     0.20 (--0.15, 0.54)     =0.26       =0.02           76
    Size \<100              470/442     0.15 (--0.17,0.48)      =0.35       \<0.00001       83
  EDTA                                                                                      
    Mentioned               358/351     0.42 (--0.00, 0.85)     =0.05       \<0.0001        86
    No-mentioned            479/362     --0.02 (--0.28, 0.24)   =0.90       =0.003          70
  NOS                                                                                       
    ≥7                      744/635     0.16 (--0.12, 0.44)     =0.25       \<0.0001        84
    \<7                     93/78       0.19 (--0.11, 0.49)     =0.22       =0.89           0
  **PLT**                   1690/1603   --0.03 (--0.18, 0.12)   =0.72       \<0.00001       73
  Geographical area                                                                         
    Eastern country         997/908     0.23 (0.14, 0.33)       \<0.00001   =0.81           0
    Western country         693/695     --0.15 (--0.33,0.03)    =0.11       =0.003          62
  Sample size of patients                                                                   
    Size ≥100               1251/1171   0.07(--0.16, 0.30)      =0.54       \<0.00001       85
    Size \<100              439/432     --0.11(--0.27, 0.06)    =0.20       =0.15           32
  EDTA                                                                                      
    Mentioned               853/669     --0.12(--0.40, 0.15)    =0.38       \<0.00001       82
    No-mentioned            837/934     0.08(--0.06, 0.22)      =0.27       =0.12           38
  NOS                                                                                       
    ≥7                      1177/1269   --0.06(--0.24, 0.12)    =0.52       \<0.00001       75
    \<7                     513/334     0.13(--0.10, 0.36)      =0.28       =0.19           41

*N*^\#^, case/control.

Difference of PDW between SSHL patients and controls {#sec4-2}
----------------------------------------------------

There were five studies reporting the association between PDW level and SSHL compared with control groups ([Figure 4](#F4){ref-type="fig"}). An *I*^2^ test indicated that the heterogeneity was significant (*P*\<0.00001, *I*^2^ = 93%); therefore, a random-effects model was applied to perform the meta-analysis. The results showed that there was statistical significance in the comparison of SSHL and control group \[SMD (95% CI) = 0.85 (0.20, 1.49)\]. The weights were evenly distributed, and sensitive analysis showed that re-synthesized result did not change obviously after fixed-effects model conducted \[SMD (95% CI) = 0.85 (0.69, 1.00)\], which suggested it is reliable. Likewise, there was no significant publication bias according to Egger's test (*P*=0.993) and Begg's test (*P*=0.806) ([Figure 5](#F5){ref-type="fig"}). With insufficient data, we did not conduct subgroup analysis.

![Differences of PDW between SSHL patients and controls](bsr-38-bsr20181183-g4){#F4}

![Begg's test (**A**) and Egger's test (**B**) for publication bias assessment of PDW.](bsr-38-bsr20181183-g5){#F5}

Difference of PLT between SSHL patients and controls {#sec4-3}
----------------------------------------------------

There were 15 studies reporting the association between PLT level and SSHL compared with control groups ([Figure 6](#F6){ref-type="fig"}). An *I*^2^ test indicated that the heterogeneity was significant (*P*\<0.00001, *I*^2^ = 73%); therefore, a random-effects model was applied to perform the meta-analysis. The results showed that there was no statistical significance in the comparison of SSHL and control group \[SMD (95% CI) = −0.03 (−0.18, 0.12)\]. Likewise, sensitive analysis with fixed-model \[SMD (95% CI) = 0.07 (−0.00 0.14)\] showed our result was reliable. Although there was publication bias according to Egger's test (*P*=0.037) and Begg's test (*P*=0.043) ([Figure 7](#F7){ref-type="fig"}), the trim and fill test suggested it did not have an impact on our result ([Figure 8](#F8){ref-type="fig"}). Similar to MPV, subgroup analysis ([Table 3](#T3){ref-type="table"}) showed that there were no significant difference in sample size ≥100 \[SMD (95% CI) = 0.07 (−0.16,0.30)\] and \<100 \[SMD (95% CI) = −0.11 (−0.27, 0.06)\], NOS ≥7 \[SMD (95% CI) = −0.06 (−0.24,0.12)\] and \<7 \[SMD (95% CI) = 0.13 (−0.10,0.36)\], and EDTA with mentioned \[SMD (95% CI) = −0.12 (−0.40,0.15)\] and no-mentioned \[SMD (95% CI) = 0.08 (−0.06,0.22)\]. But in respect of geographical area, there was significant result in Eastern country \[SMD (95% CI) = 0.23 (0.14, 0.33)\], but not in Western country \[SMD (95% CI) = −0.15 (−0.33, 0.03)\].

![Differences of PLT between SSHL patients and controls](bsr-38-bsr20181183-g6){#F6}

![Begg's test (A) and Egger's test (B) for publication bias assessment of PLT.](bsr-38-bsr20181183-g7){#F7}

![Filled funnel plot for publication bias assessment of PLT](bsr-38-bsr20181183-g8){#F8}

Discussion {#sec5}
==========

Although platelet parameters, such as MPV, PDW, and PLT, have exhibited diagnostic significance in various diseases and conditions \[[@B25],[@B26]\], it is unclear that whether there exists clinic significance of them in SSHL. This study is the first meta-analysis of published studies to explore the relationship between platelet parameters and SSHL. Our results did not support there was relationship between MPV and SSHL, but PLT may be applied to clinical practice of Eastern country SSHL patients.

SSHL is a clinical condition characterized by the acute onset of unilateral or bilateral hearing loss greater than 30 dB over three consecutive frequencies in less than 72 h. Different theories about the pathogenesis of SSHL have been proposed, including vascular incidents, vascular occlusions, viral, bacterial, and protozoan infections, intracochlear membrane rupture, autoimmune disorders, and side effects from ototoxic medications \[[@B27]\]. There are a series of studies that prove that the disturbance of blood circulation plays a large role in SSHL \[[@B28]\]. As the cochlear artery is a terminal branch of the anterior inferior cerebellar artery, with a small inner diameter and insignificant collateral circulation, any pathology in this location that influences collateral blood supply may damage the cochlea and cause acute hearing loss \[[@B10]\].

Platelets are the smallest cells of the peripheral blood, and they are involved in hemostasis and the formation of thrombosis in blood vessels. Mediators and substances released by platelets play a significant role in the progress of coagulation, inflammation, thrombosis, and atherosclerosis. MPV is a commonly used parameter to indicate the volume, function, and activity of platelets. It has been proven that MPV levels increase in vascular events such as atherosclerosis, acute syndromes, venous and arterial thrombosis, or thromboembolism \[[@B29]\]. The increased MPV contributes to the prethrombotic state in acute syndromes. PLT and PDW are other important platelet parameters. PLT refers to the number of platelets in per unit volume of blood. PDW reflects the variation in size of platelets in a blood sample.

In recent years, a series of studies concerning the relationship between platelet parameters and the occurrence and severity of SSHL have been performed, but there was no consistent conclusion. Ulu et al. \[[@B7]\] and Durmus et al. \[[@B8]\] observed significantly higher MPV, PDW, and PLT in SSHL patients than controls and concluded that they could be taken into consideration as potential novel markers in the assessment of SSHL. By contrast, Lee et al. \[[@B9]\] reported the relationship between MPV and SSHL in children and found MPV was significantly decreased in the SSHL group, which might reflect that the mechanisms of pediatric SSHL are different from those of adults. We did not further analyze the differences between children and adults due to the limitation of fewer studies about the former. Furthermore, other studies (10--16) have shown no statistical correlation between platelet parameters and SSHL. It is unusual to find that there seems to be a paradox, which limits our interpretation of these experimental results.

MPV, PDW, and PLT are susceptible to many vascular risk factors including age, smoking, diabetes mellitus, hypertension, hyperlipidemia, and obesity \[[@B30]\]. It is advisable for researchers to rule out patients with active inflammations, suspicion of an autoimmune inner ear disease, known etiology of SSHL, history of otologic surgery or head and neck trauma, previously diagnosed cardiovascular disease, chronic diseases such as diabetes mellitus, hypertension, hyperlipidemia, obesity, antiaggregant or anticoagulant drug use, chronic alcohol consumption, and smoking. These factors may influence the outcome of MPV, PDW, and PLT assessments. Although there are a number of exclusion criteria in the studies to standardize the results, MPV, PDW, and PLT may still be affected by many other minor factors, such as nasal septum deviations, major depression, insulin resistance, and erectile dysfunction \[[@B17],[@B31]\], which were not taken into consideration and thus not excluded. Our aim with the exclusion criteria was to show the possible correlation with SSHL and platelet parameters but, in daily practice, comorbidities are frequently observed in patients with SSHL. It is impossible for us to adjust for all the variables between SSHL and control groups.

In the methods section, in order to measure MPV, venous blood samples were collected into tubes containing EDTA. However, in an earlier study, Bath et al. \[[@B34]\] found that measurements in EDTA can be unreliable since MPV increases significantly in a time-dependent manner. One can readily measure MPV by clinical hematology analyzers using sodium citrate as the anticoagulant. Therefore, we performed a pooled analysis about EDTA, although only five studies \[[@B7],[@B8],[@B12],[@B16],[@B21]\] reported measuring MPV with EDTA. The analysis showed that the results did not change \[SMD (95% CI) = -0.12(-0.40, 0.15)\], which suggested that EDTA did not influence final results.

In respect of MPV in SSHL, pooled results did not support there exit the association, but quality of included studies may be main resource of heterogeneity. Although we discover PDW exhibit difference between SSHL group and control group, there was no enough data to explore resources of heterogeneity, in addition to considering small studies included, we could not reach a conclusion impetuously. A total of 16 studies included to study the relationship between PLT and SSHL, our result also did not uphold the relationship completely. However, subgroup analysis by geographical area showed that there was significant difference in Eastern country, while other subgroups not, which suggested geographical area may be the source of heterogeneity. Sensitive analysis revealed that our results were stable. And there was no publication bias, if any, it did not impact our results. All of them demonstrated our results were reliable.

There were several limitations exiting in this analysis need to be carefully considered. First, all the including researches were case--control studies, and we could not ensure other factors matched completely. Second, in terms of PDW, too few articles included to find the source of heterogeneity, so we could not reach a conclusion. Third, although we have implemented full subgroups analysis, we failed to discover the other sources heterogeneity about MPV and PLT. Finally, with insufficient data, we did not explore the threshold.

In summary, we concluded that MPV failed to apply to diagnosis and monitor of SSHL, while PLT might be a positive factor for SSHL in Eastern country. The clinical significance of PDW for SSHL is remaining to be confirmed with more well-designed and large-scale studies.
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:   mean platelet volume
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